Trials / Completed
CompletedNCT01810380
Brexpiprazole in Patients With Acute Schizophrenia
Interventional, Randomised, Double-blind, Parallel-group, Placebo-controlled, Active-reference, Flexible-dose Study of Brexpiprazole in Patients With Acute Schizophrenia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 468 (actual)
- Sponsor
- H. Lundbeck A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To determine the efficacy and safety of brexpiprazole for the treatment of adults experiencing an acute episode of schizophrenia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Once daily as tablets and capsules, orally |
| DRUG | Brexpiprazole | 2-4 mg/day, once daily, tablets, orally |
| DRUG | Quetiapine extended release | 400-800 mg/day, once daily, encapsulated tablets, orally |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2013-03-13
- Last updated
- 2017-03-16
- Results posted
- 2016-03-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01810380. Inclusion in this directory is not an endorsement.